All In Biotech

Drug Trial Radar · NCT06665256

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Refractory Idiopathic Inflammatory Myopathies (IIM)

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

21

Actual

Start

Dec 17, 2024

Primary completion

Mar 9, 2029

Study completion Nov 29, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)

Conditions

  • Idiopathic Inflammatory Myopathies

Interventions

  • Rapcabtagene autoleucelBiological

    Single infusion of rapcabtagene autoleucel after lymphodepleting therapy with fludarabine (adjusted based on renal impairment) and cyclophosphamide daily for 3 days.

  • Active Comparator OptionOther

    Investigator choice of treatment as per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving moderate- to-major improvement in Total Improvement Score (TIS) at Week 52Time frame: Week 52

Locations

68 sites in 15 countries. Site status is shown where the registry gives one.

  • University Of Alabama

    Birmingham, Alabama

  • FL Medical Clinic Orlando Health

    Zephyrhills, Florida

  • Augusta University Georgia

    Augusta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University Of Iowa

    Iowa City, Iowa

  • Duke Clinical Research Institute

    Durham, North Carolina

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Baylor University Medical Center

    Dallas, Texas

  • Houston Methodist Hospital

    Houston, Texas

  • LDS Hospital

    Salt Lake City, Utah

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Rennes, France

  • Novartis Investigative Site

    Aachen, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Nuremberg, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, Germany

  • Novartis Investigative Site

    Jena, Thuringia, Germany

  • Novartis Investigative Site

    Haifa, Israel

  • Novartis Investigative Site

    Ramat Gan, Israel

  • Novartis Investigative Site

    Tel Aviv, Israel

  • Novartis Investigative Site

    Ancona, AN, Italy

  • Novartis Investigative Site

    Brescia, BS, Italy

  • Novartis Investigative Site

    Monza, MB, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Rozzano, MI, Italy

  • Novartis Investigative Site

    Verona, VR, Italy

  • Novartis Investigative Site

    Fukuoka, Japan

  • Novartis Investigative Site

    Ishikawa, Japan

  • Novartis Investigative Site

    Kyoto, Japan

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.